Compare Incyte Corporation (INCY) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs McCormick & Company, Incorporated — how do they compare? Incyte Corporation trades at $120.65 (market cap $24.54B), while McCormick & Company, Incorporated trades at $52.83 (market cap $14.22B). The key difference: Incyte Corporation is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MKC | |
|---|---|---|
Market Cap | $24.54B | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $72.26 |
52-Week Low | $81.61 | $45.60 |
Enterprise Value | $20.04B | $18.82B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
MKC trades at $53.13, up 0.32% today, with a bullish technical signal and strong profitability metrics including a 21.91% net income margin and 25.7% ROE. Recent Q2 2026 results beat expectations, driven by acquisitions and margin expansion. The pending Unilever Foods merger, expected to close in 2027, dominates news flow and offers transformative growth potential.
The outlook is positive, with a consensus price target of $59.67 implying 12% upside. Key opportunities include merger synergies and sustained dividend growth, while risks involve integration execution and soft consumer volumes. Analysts are mixed but lean bullish on valuation and strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
